Acknowledgments We would like to thank Dr. Brian D. Dynlacht, New York University for providing us microRNA resistant E2F3a and E2F3b expression plasmids. References 1. Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9–22. 2. Zygogianni A, Kyrgias G, Mystakidou K, Antypas C, Kouvaris J, et al. (2011) Potential role of the alcohol and smoking in the squamous cell carcinoma of the head and neck: review of the current literature and new perspectives. Asian Pac J Cancer Prev 12: 339–344. 3. Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology 11: 781–789. 4. Richey LM, Shores CG, George J, Lee S, Couch MJ, et al. (2007) The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 136: 98–103. 5. Iorio MV, Croce CM (2009) MicroRNAs in Cancer: Small Molecules With a Huge Impact. Journal of Clinical Oncology 27: 5848–5856. 6. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843–854. 7. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376–385. 8. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866. 9. Meltzer PS (2005) Cancer genomics: small RNAs with big impacts. Nature 435: 745–746. 10. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15: 1443–1461. 11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257–2261. 12. Baffa R, Fassan M, Volinia S, O’Hara B, Liu CG, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219: 214–221. 13. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838. 14. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, et al. (2009) Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401. 15. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, et al. (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736–745. 16. Ramdas L, Giri U, Ashorn CL, Coombes KR, El-Naggar A, et al. (2009) miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 31: 642–654. 17. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, et al. (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377: 114–119. 18. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569–7576. 19. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, et al. (2008) The MYCN oncogene is a direct target of miR-34a. Oncogene 27: 5204–5213. 20. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017–5022. 21. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275: 44–53. 22. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104: 15472–15477. 23. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745–752. 24. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731–743. 25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211–215. 26. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel miR-34a Inhibits HNSCC Tumor Growth Author Contributions Conceived and designed the experiments: PK BK TNT. Performed the experiments: BK AY PK. Analyzed the data: BK PK. Contributed reagents/materials/analysis tools: JL TNT. Wrote the paper: PK BK. sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586–1593. 27. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, et al. (2011) Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197–204. 28. Chong J-L, Tsai S-Y, Sharma N, Opavsky R, Price R, et al. (2009) E2f3a and E2f3b Contribute to the Control of Cell Proliferation and Mouse Development. Mol Cell Biol 29: 414–424. 29. Asp P, Acosta-Alvear D, Tsikitis M, van Oevelen C, Dynlacht BD (2009) E2f3b plays an essential role in myogenic differentiation through isoform-specific gene regulation. Genes Dev 23: 37–53. 30. Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, et al. (2008) E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene 27: 6561–6570. 31. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581–8589. 32. Walk E, Weed S (2011) Recently Identified Biomarkers That Promote Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. Cancers 3: 747–772. 33. Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5: 1087–1098. 34. Gou D, Zhang H, Baviskar PS, Liu L (2007) Primer extension-based method for the generation of a siRNA/miRNA expression vector. Physiol Genomics 31: 554–562. 35. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA (2004) Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279: 40511–40520. 36. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, et al. (2003) Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model. Clinical Cancer Research 9: 5161–5170. 37. Izu A, Yanagida H, Sugimoto K, Fujita S, Sakata N, et al. (2011) Pathogenesis of focal segmental glomerular sclerosis in a girl with the partial deletion of chromosome 6p. Tohoku J Exp Med 223: 187–192. 38. Mezquita P, Parghi SS, Brandvold KA, Ruddell A (2004) Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene 24: 889–901. 39. Kumar P, Coltas IK, Kumar B, Chepeha DB, Bradford CR, et al. (2007) Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK- survivin signaling pathway that is independent of cytochrome c release. Cancer Res 67: 1193–1202. 40. Kumar P, Ning Y, Polverini PJ (2008) Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest 88: 740–749. 41. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43–66. 42. Pugliano FA, Piccirillo JF, Zequeira MR, Emami B, Perez CA, et al. (1997) Clinical-severity staging system for oropharyngeal cancer: five-year survival rates. Arch Otolaryngol Head Neck Surg 123: 1118–1124. 43. Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, et al. (1999) Clinical-severity staging system for oral cavity cancer: five-year survival rates. Otolaryngol Head Neck Surg 120: 38–45. 44. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, et al. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23: 1229–1234. 45. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9–22. 46. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, et al. (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26: 3138–3146. 47. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, et al. (2009) Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15: 637–647. 48. Li B, Hu Y, Ye F, Li Y, Lv W, et al. (2010) Reduced miR-34a Expression in Normal Cervical Tissues and Cervical Lesions With High-Risk Human Papillomavirus Infection. International Journal of Gynecological Cancer 20: 597–604 510.1111/ IGC.1110b1013e3181d63170. 49. Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA (2011) Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 33: 504–512. 50. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, et al. (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25: 654–661. PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e37601